Section Arrow
URGN.NASDAQ
- UroGen Pharma Ltd
Quotes are at least 15-min delayed:2024/10/31 19:15 EDT
Last
 12.28
-0.74 (-5.68%)
Day High 
13.13 
Prev. Close
13.02 
1-M High
13.64 
Volume 
395.06K 
Bid
12.35
Ask
13.5
Day Low
12.24 
Open
13.02 
1-M Low
11.295 
Market Cap 
548.33M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 12.43 
20-SMA 12.42 
50-SMA 13.05 
52-W High 20.7 
52-W Low 10.6001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.09/-3.53
Enterprise Value
647.72M
Balance Sheet
Book Value Per Share
0.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
82.71M
Operating Revenue Per Share
1.72
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.